Tislelizumab by BeiGene for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

Tislelizumab is under clinical development by BeiGene and currently in Pre-Registration for Esophageal Squamous Cell Carcinoma (ESCC).

Source link
#Tislelizumab #BeiGene #Esophageal #Squamous #Cell #Carcinoma #ESCC #Likelihood #Approval